The CATNIP trial– a double blind randomized placebo controlled trial – tested whether treating cat allergy tested whether giving a monoclonal antibody called tezepelumab, which interferes with TSLP signaling, plus cat allergy shots to people with allergic rhinitis caused by cat allergens would safely provide better and longer-lasting symptom relief than allergy shots alone.
In an article published in JACI, the study team showed that the combination therapy resulted in a reduction in “peak nasal symptoms” over immunotherapy alone one year after treatment was completed, demonstrating that the combination improved sustained unresponsiveness.
Mechanistic analyses showed that the combination treatment resulted in changes in gene network activity that reduced the activation of allergy-related immune cells on the inner lining of the nose, helping suppress allergic nasal symptoms.
NIH Press Release: Monoclonal antibody improves cat allergen immunotherapy
MedPageToday: Fight Cat Allergies With Newest Asthma Drug?